Alzheimer’s disease is the most common cause of dementia, affecting millions worldwide and expected to impact over 150 million people by 20501 . While many factors contribute to Alzheimer’s, genetics play a crucial role in determining risk and disease onset2 . Recent research has identified a specific genetic variant, APOE ε4, as a major cause of a genetically defined form of Alzheimer’s disease, reshaping how the disease is understood and treated3 . This discovery has important implications for treatment options and genetic testing recommendations.
A New Genetic Variant Discovery
Alzheimer’s disease is marked by the buildup of abnormal proteins in the brain, including amyloid-beta plaques and tau tangles, which lead to nerve cell death and cognitive decline4 . Among the many genes linked to Alzheimer’s, the apolipoprotein E gene (APOE) stands out as the strongest genetic risk factor for late-onset Alzheimer’s disease5 . APOE has three common variants: ε2, ε3, and ε4. The ε4 variant increases the risk and severity of Alzheimer’s, while ε2 may offer some protection2 .
People inherit two copies of the APOE gene, one from each parent. Having one copy of APOE ε4 doubles or triples the risk of developing Alzheimer’s, but having two copies (called APOE ε4 homozygosity) increases the risk even more dramatically, by 8 to 12 times2 . APOE ε4 homozygotes tend to develop Alzheimer’s pathology earlier, with amyloid accumulation detectable by midlife and symptoms often beginning in the mid-60s5 3.
A recent study primarily involving people of European descent found that nearly all APOE ε4 homozygotes develop abnormal amyloid levels by age 65, and most show Alzheimer’s pathology starting as early as age 553 . This suggests a newly defined genetic form of Alzheimer’s disease that is highly predictable in its onset and progression3 . APOE ε4 homozygotes represent about 2% of the population but account for approximately 15% of Alzheimer’s cases3 .
However, the risk conferred by APOE ε4 varies by ethnicity, with some populations showing lower risk despite carrying the allele6 7. The lack of ethnic diversity in many studies limits the universal applicability of these findings, highlighting the need for further research in diverse populations6 .
Beyond APOE, several other genes have been linked to Alzheimer’s risk, including ABCA7, CLU, CR1, PICALM, PLD3, TREM2, and SORL12 . These genes influence processes such as cholesterol metabolism, beta-amyloid clearance, immune response, and neuronal communication, all of which contribute to disease development2 . However, these are risk genes rather than deterministic causes.
In contrast, rare deterministic genes cause early-onset Alzheimer’s disease, which typically appears before age 65. These include mutations in the amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) genes8 . Individuals inheriting these mutations have a very high likelihood of developing Alzheimer’s symptoms early in life8 .
Recent discoveries also include novel genetic mutations linked to Alzheimer’s, such as a repeated DNA segment in the CASP8 gene that produces toxic polyGR proteins distinct from amyloid or tau9 . This mutation doubles the risk of late-onset Alzheimer’s and suggests additional genetic contributors to the disease9 .
| Genetic Variant | Role in Alzheimer’s Disease | Risk Level | Typical Onset Age | Population Prevalence |
|---|---|---|---|---|
| APOE ε4 (homozygous) | Strongest risk factor for late-onset AD; amyloid accumulation | Very high (8–12x risk) | Mid-60s symptoms; pathology by 55–65 | ~2% general population; 15% of AD cases5 3 |
| APP, PSEN1, PSEN2 | Deterministic genes causing early-onset AD | Near-certain | Before 65 | Rare; cause 10–15% of early-onset cases8 |
| CASP8 polyGR mutation | Novel toxic protein buildup | Doubles risk | Late-onset | Unknown; found in ~56% of studied AD brains9 |
“While most Alzheimer’s research has focused on the buildup of amyloid beta and tau, the polyGR proteins we’ve found in Alzheimer’s brains were unexpected and completely different.”
— Laura Ranum, PhD, University of Florida9
Potential Treatment Applications
The identification of APOE ε4 homozygosity as a genetic cause of a specific form of Alzheimer’s disease opens new avenues for targeted treatment strategies10 . Current Alzheimer’s treatments mainly address symptoms, such as memory loss and cognitive decline, but do not halt or reverse the underlying brain cell damage11 .
Recent advances include disease-modifying therapies that target amyloid plaques, a hallmark of Alzheimer’s pathology. Monoclonal antibodies like lecanemab (Leqembi) and donanemab (Kisunla) have been approved for early-stage Alzheimer’s and mild cognitive impairment due to Alzheimer’s11 . These therapies work by preventing amyloid plaques from forming and helping clear existing plaques from the brain11 .
However, these treatments carry risks. Lecanemab, for example, has a black-box warning for brain swelling and bleeding, particularly in APOE ε4 homozygotes, who are at higher risk for these serious side effects5 11. Because of this, the FDA recommends brain MRI screening before and during treatment and genetic testing for APOE ε4 status to assess risk11 .
“This treatment is a multi-factorial approach. Taking an approach with multiple effects is, we believe, the best way to stop the cells from dying.”
— Yoke Peng Loh, PhD, National Institutes of Health12
Other promising therapeutic approaches include:
- Targeting APOE4 directly: Developing treatments that specifically address the harmful effects of APOE ε4 could benefit high-risk individuals5 .
- Reducing inflammation: Alzheimer’s involves chronic brain inflammation, and drugs like sargramostim (Leukine) are being studied for their potential to stimulate protective immune responses11 .
- Blocking beta-amyloid production: Beta- and gamma-secretase inhibitors aim to reduce amyloid formation but have shown limited success and side effects in trials11 .
- Preventing tau tangles: Tau aggregation inhibitors and vaccines are under clinical investigation to stop tau protein from forming harmful tangles11 .
- Gene therapy: Experimental gene therapies that boost neuroprotective molecules like neurotrophic factor alpha-1 (NF-alpha-1) show promise in protecting neurons and reducing pathology in animal models12 .
Lifestyle factors that promote heart and vascular health, such as regular exercise and a heart-healthy diet, may also help delay Alzheimer’s onset or progression11 . This is important because cardiovascular conditions like high blood pressure and diabetes increase dementia risk11 .
Disease-modifying treatments offer hope for people with high genetic risk, especially APOE ε4 homozygotes, but careful monitoring is essential due to increased side effect risks. Ongoing research aims to develop safer, more effective therapies tailored to genetic profiles11 56.
Genetic Testing Recommendations
Despite the strong link between APOE ε4 homozygosity and Alzheimer’s disease, routine genetic testing for APOE status is not widely recommended in clinical practice5 . This is due to the complexity of interpreting test results and the current lack of preventive treatments that can alter disease risk based on genetic information5 .
Genetic testing may be considered in specific situations:
- Individuals with a family history of early-onset Alzheimer’s or multiple affected relatives may benefit from testing for deterministic genes like APP, PSEN1, and PSEN28 .
- APOE testing can be useful before starting anti-amyloid therapies such as lecanemab, to assess the risk of side effects5 11.
- People interested in research participation or family planning may also consider genetic counseling and testing5 8.
Genetic testing for Alzheimer’s risk is a complex decision. Consultation with a healthcare provider or genetic counselor is essential to understand the benefits, limitations, and potential consequences of testing5 .
However, having one or two copies of APOE ε4 does not guarantee developing Alzheimer’s, and many people without the allele still develop the disease2 7. Therefore, test results should be interpreted cautiously and in consultation with healthcare professionals or genetic counselors5 .
Key points about genetic testing for Alzheimer’s risk:
- Routine APOE testing is not recommended for asymptomatic individuals5 .
- The risk associated with APOE ε4 varies by ethnicity and other factors, limiting the predictive value of testing6 7.
- Testing for deterministic early-onset genes is typically reserved for symptomatic individuals or those with a strong family history8 .
- Genetic information may have implications for insurance and employment, so counseling is important before testing5 .
- More research is needed to refine testing guidelines and develop interventions based on genetic risk6 .
